Cochrane Evidence Synthesis and Methods ►

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.

This is a protocol.

Health topics:

Cancer > Lung > Non-small cell

Lungs & airways > Lung cancer > Non-small cell

Published:

18 March 2022

Authors:

Occhipinti M, Ferrara R, Imbimbo M, Simeon V, Fiscon G, Marchal C, Skoetz N, Viscardi G

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Occhipinti M, FerraraR, ImbimboM, SimeonV, FisconG, MarchalC, SkoetzN, ViscardiG.Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation (Protocol). Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD015140. DOI: 10.1002/14651858.CD015140.